• Early response to olanzapine LAI was assessed following 4 weeks of treatment, which is later than that used in most other studies with oral antipsychotics (2 weeks). This was done because 4 weeks represented a 1-injection interval for many of the patients in this trial and was therefore the earliest reasonable point at which to re-evaluate treatment. In addition, the half-life of olanzapine LAI is approximately 4 weeks. 10 • This analysis focused on acutely ill, hospitalized patients who were severely ill. Results cannot be extrapolated to patients with less severe symptomology or who are earlier in their course of illness.
• Early response to olanzapine LAI (at Week 4) was found to predict subsequent response (at Week 8) with high sensitivity, specificity, PPV, NPV, and an overall accuracy level of 79%.
• Early responders differed significantly from early nonresponders by having higher PANSS Total, PANSS depression, and PANSS Negative symptom scores at baseline. There were no other differences in baseline characteristics.
• Time to discontinuation was significantly shorter for early non-responders than for early responders (p=.007).
• Early responders had significantly greater changes from baseline in LS mean PANSS Total score at every time point (p<.001), and by Week 8, they had over twice the reduction in LS mean PANSS Total score than early nonresponders had (37.0 points vs. 15.4 points).
• At Week 8, early responders had statistically significantly greater improvement than early non-responders in all subscores of the PANSS, all QLS measures, and also in the Mental Health and Social Functioning subscales of the SF-36.
• Nearly one quarter of early non-responders to olanzapine LAI (23% or 22/96) demonstrated response by Week 8. Lack of early improvement in 2 PANSS subscale scores -Negative symptoms and Disorganized Thoughtspredicted continued non-response at end point among the early non-responders. Specifically, lack of at least a 3-point drop in Negative symptoms subscale scores and lack of at least a 3-point drop in Disorganized Thoughts subscale scores at 4 weeks predicted continued nonresponse.
Objective: Early non-response to oral antipsychotics was previously shown to be a robust predictor of subsequent non-response to continued treatment with the same oral antipsychotic medication in the treatment of schizophrenia. This study assessed whether early response or early non-response to treatment can serve as a clinical marker in the treatment of schizophrenia with an atypical antipsychotic in long-acting injection formulation (depot).
Methods:
This post-hoc analysis used data (n=233) from an 8-week randomized, double-blind, placebocontrolled study of olanzapine long-acting injection (olanzapine LAI) in the treatment of inpatients with schizophrenia. Early response to olanzapine LAI was defined as a ≥30% improvement on the PANSS total score (items scored 0-6) from baseline to 4 weeks of treatment. Subsequent response was defined as a ≥40% improvement on the PANSS total score from baseline to endpoint. 
Introduction
• Clinicians had long believed in a delayed onset of action for oral antipsychotic medication and recommended re-evaluation of a treatment regimen only after 4 to 8 weeks of treatment 1 ; however, more recent research has not lent support to the "delayed onset" hypothesis. [2] [3] [4] • Studies have shown that in the treatment of schizophrenia, non-response to an oral antipsychotic medication as early as Week 1 or 2 can reliably predict subsequent non-response to continued use of the same medication. [5] [6] [7] [8] This has been found to be true for multiple antipsychotic drugs, including oral olanzapine, and may help clinicians decide earlier in the course of treatment whether to change the treatment regimen.
• It is not known whether early response/non-response to therapy is a robust predictor of subsequent response when the antipsychotic is in an injectable ("depot") formulation, such as olanzapine long-acting injection (olanzapine LAI).
• The efficacy, safety, and tolerability of olanzapine LAI have been demonstrated in several studies, including 2 randomized double-blind trials. 9,10 • Olanzapine LAI has been shown to have early onset of action with clinical effects detectable as early as the first week of treatment. 9 Although olanzapine LAI provides therapeutic drug levels following the first injection, drug levels continue to accumulate, reaching steady state olanzapine plasma concentrations approximately 3 months after initiation of therapy. 10 • Given that olanzapine LAI takes longer to reach steady state than oral olanzapine and given that olanzapine LAI is dosed as frequently as every 2 weeks and as infrequently as every 4 weeks, it is not known what might constitute "early" response and whether early response would be predictive of subsequent response.
• In addition, it is unclear whether patients who do not initially respond to olanzapine LAI are likely to respond with further treatment. Because use of olanzapine LAI may involve overcoming patient resistance to an injectable formulation or may be viewed as a patient's "last resort," it is important not to discontinue therapy prematurely.
Primary Objective Secondary Objectives
To assess whether response to olanzapine LAI at Week 4 of treatment predicts response/non-response at Week 8 of treatment in severely ill, hospitalized patients with chronic schizophrenia.
•To identify patient characteristics and baseline illness parameters that help differentiate early responders from early non-responders who are treated with olanzapine LAI.
•To compare the baseline-to-endpoint change in outcome measures between early responders and early non-responders to treatment with olanzapine LAI.
•To determine the likelihood of response to treatment at Week 8 for those patients who do not demonstrate early response (at Week 4) and to identify factors predictive of later response among early nonresponders.
Methods
• This was a post-hoc analysis of data from an 8-week • Time until discontinuation was compared for early responder and early non-responder groups using product-limit survival analysis methodology based on the Kaplan-Meier method, and group differences were assessed using the log-rank test.
• Least square (LS) mean change over time from baseline in PANSS Total score for early responders and early non-responders were compared based on a mixedmodel repeated measures model with baseline PANSS Total score, investigator, responder status, week, and responder status-by-week interaction terms.
• Baseline-to-endpoint change in PANSS subscores, QLS measure scores, and SF-36 construct scores for early responders and early non-responder groups were compared between groups based on an analysis of covariance model with baseline PANSS Total score, investigator, and responder status.
• Used a regression analysis to fit change from baseline to Week 4 in the 5 Davis factors of the PANSS (Positive, Negative, Disorganized Thoughts, Impulsivity/Hostility, and Anxiety/Depression) into a model predicting response at Week 8 for those patients who did not initially meet response criteria.
• Results considered significant at the p<.05 level. Later response was defined as a ≥40% improvement in PANSS 0-6 Total score following 8 weeks of antipsychotic therapy. Early response was defined as a ≥30% improvement in PANSS 0-6 Total score following 4 weeks of antipsychotic therapy. 
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Limitations
Abbreviations: LS=Least Square; QLS=Quality of Life Scale. Early response was defined as a ≥30% improvement over baseline in PANSS Total score at Week 4. Abbreviations: LS=Least Square; PANSS=Positive and Negative Syndrome Scale. Early response was defined as a ≥30% improvement over baseline in PANSS Total score at Week 4.
